Want to see AU:AT1 full AI Analyst Report?
Atomo Diagnostics Ltd. (AT1) AI Stock Analysis
Atomo Diagnostics Ltd.
(ASX:AT1)
The overall score is low primarily because Atomo Diagnostics shows chronic losses, shrinking equity, and consistently negative operating and free cash flows despite recent revenue growth and low debt, pointing to a high-risk financial profile. Technical indicators reinforce this cautious view, with the share price trading below all major moving averages and momentum signals mixed to weak. Valuation is also unattractive, as a negative P/E and lack of dividend yield offer little current earnings or income support for investors.
Atomo Diagnostics Ltd. (AT1) vs. iShares MSCI Australia ETF (EWA)
- Market Cap
- AUD 12.63M
- Dividend Yield
- ―
- Average Volume (3M)
- 976.69K
- Price to Earnings (P/E)
- -3.3
- Beta (1Y)
- 0.58
- Revenue Growth
- 40.65%
- EPS Growth
- 45.45%
- Country
- Australia
- Employees
- 85
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Atomo Diagnostics Ltd. Business Overview & Revenue Model
Company Description
Established in 2010 and based in Leichhardt, Australia, Atomo Diagnostics Limited is a global enterprise focused on the innovation and commercialization of medical devices. The company provides swift-result diagnostic tools designed for various appli...
How the Company Makes Money
Atomo Diagnostics makes money primarily by supplying its proprietary rapid test device platforms and associated components to third parties that manufacture and sell completed diagnostic tests. Revenue is generated through sales of physical products...
Atomo Diagnostics Ltd. Financial Statement Overview
Summary
Overall financial quality is weak: revenue grew about 36% in the latest year and leverage is very low, but the company has reported losses every year from 2021 to 2026, equity has fallen sharply, assets have more than halved, and operating and free cash flows remain persistently negative.
Income Statement
24NegativeBalance Sheet
42NeutralCash Flow
28Negative| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.33M | 5.33M | 3.79M | 4.09M | 2.54M | 12.34M |
| Gross Profit | -2.43M | -2.43M | 1.79M | 1.44M | -6.08M | -1.85M |
| EBITDA | -4.26M | -4.26M | -4.25M | -6.12M | -9.00M | -4.72M |
| Net Income | -3.51M | -3.51M | -4.97M | -6.85M | -9.96M | -5.71M |
Balance Sheet | ||||||
| Total Assets | 10.83M | 10.83M | 9.28M | 11.38M | 16.47M | 26.62M |
| Cash, Cash Equivalents and Short-Term Investments | 3.71M | 3.71M | 3.22M | 3.69M | 6.47M | 12.97M |
| Total Debt | 373.08K | 373.08K | 185.10K | 141.19K | 254.88K | 340.81K |
| Total Liabilities | 3.12M | 3.12M | 2.30M | 1.29M | 1.68M | 1.81M |
| Stockholders Equity | 7.71M | 7.71M | 6.98M | 10.08M | 14.79M | 24.81M |
Cash Flow | ||||||
| Free Cash Flow | -3.40M | -3.40M | -1.99M | -4.70M | -6.25M | -5.11M |
| Operating Cash Flow | -3.37M | -3.37M | -1.96M | -4.69M | -5.85M | -2.81M |
| Investing Cash Flow | -35.32K | -35.32K | -33.89K | -16.08K | -401.28K | -2.31M |
| Financing Cash Flow | 3.81M | 3.81M | 1.46M | 1.87M | -170.75K | 17.61K |
Atomo Diagnostics Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:AT1, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and below the 200-day MA of 0.03, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 0.00 is Positive, neither overbought nor oversold. The STOCH value of -11.11 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:AT1.
Atomo Diagnostics Ltd. Peers Comparison
Overall Rating
AU:CMP54Neutral
AU:EMV50Neutral
AU:CYC48Neutral- AU:AT141Neutral
AU:MX141Neutral
AU:IPD39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| AU:CMP | 54Neutral | AUD 47.94M | 209.09 | 0.93% | ― | 18.54% | ― |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| AU:EMV | 50Neutral | AUD 139.67M | -15.83 | -46.84% | ― | ― | 20.40% |
| AU:CYC | 48Neutral | AUD 53.44M | -3.11 | -62.14% | ― | 12.05% | -31.71% |
| AU:AT1 | 41Neutral | AUD 12.63M | -3.33 | -48.97% | ― | 40.65% | 45.45% |
| AU:MX1 | 41Neutral | AUD 27.10M | -2.24 | -188.06% | ― | 15.58% | 37.17% |
| AU:IPD | 39Underperform | AUD 14.66M | -0.34 | -259.31% | ― | 14.85% | -1.74% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AU:AT1 | Atomo Diagnostics Ltd. | 0.01 | -0.02 | -53.33% | |
| AU:CMP | Compumedics Limited | 0.22 | -0.10 | -31.25% | |
| AU:IPD | Impedimed Limited | 0.01 | -0.02 | -63.16% | |
| AU:CYC | Cyclopharm Limited | 0.46 | -0.20 | -30.30% | |
| AU:MX1 | Micro-X Ltd. | 0.03 | -0.09 | -73.33% | |
| AU:EMV | EMvision Medical Devices Ltd. | 1.47 | -0.43 | -22.63% |
Atomo Diagnostics Ltd. Corporate Events
Atomo Diagnostics Issues Cautious Q1 2027 Results Overview
Atomo Diagnostics has released an overview of its first quarter 2027 results, accompanied by extensive disclaimers that frame the material as general information rather than investment advice. The document stresses that the presentation is incomplete...
Atomo boosts HIV and syphilis test pipeline as Q1 revenue surges 140%
Atomo Diagnostics has expanded its proprietary rapid-testing pipeline through a new memorandum of understanding with Innovation Scientific to develop a fourth-generation HIV rapid test built on its Galileo cassette platform, complementing its existin...
Atomo Diagnostics Strikes Deal to Develop Generation 4 HIV Rapid Test
Atomo Diagnostics has signed a Memorandum of Understanding with Innovation Scientific to develop and commercialise a Generation 4 HIV rapid assay using Atomo’s Galileo cassette platform. Innovation Scientific will lead further development, anal...
Atomo Diagnostics Updates Timing for Q1 FY27 Investor Webinar
Atomo Diagnostics has rescheduled the start time of its Q1 FY27 quarterly investor webinar to 2 p.m. AEDT on 3 November 2026, to be hosted by chief executive Cheri Walker and financial controller Suzy Elhlou. The company is directing stakeholders to...
Atomo Diagnostics Options Lapse, Tidying Up Capital Structure
Atomo Diagnostics has reported the cessation of 275,000 listed options (AT1AO) that expired on 22 August 2026 without being exercised or converted. The lapse of these options marginally reduces the pool of potential future equity, leaving existing sh...
Atomo Diagnostics Options Lapse, Streamlining Capital Structure
Atomo Diagnostics has confirmed that 2,120,000 options, exercisable at $0.035 and due to expire on 1 July 2027, have ceased following expiry without being exercised. The cessation reduces the company’s pool of outstanding convertible securities...
Atomo Diagnostics Schedules Q1 FY27 Investor Webinar to Boost Stakeholder Engagement
Atomo Diagnostics has announced a Q1 FY27 quarterly investor webinar to be held on 3 November 2026, hosted by CEO Cheri Walker and Financial Controller Suzy Elhlou. The company is directing investors to pre-register online and to use its dedicated In...
Atomo Diagnostics Sets Virtual AGM for 5 November 2026
Atomo Diagnostics Limited has called its Annual General Meeting for 5 November 2026, to be held virtually via a Zoom webinar at 10:00 a.m. AEDT, reflecting its continued use of remote participation technology for shareholder meetings. The company is...
Atomo Diagnostics Issues FY26 Results Overview Disclaimer
Atomo Diagnostics Ltd., an ASX-listed medical diagnostics company, develops rapid point-of-care testing solutions for healthcare markets that require fast and accessible diagnostic tools. Its product portfolio is aimed at improving usability and accu...
Atomo Diagnostics to Present FY26 Results and Strategy in Investor Webinar
Atomo Diagnostics will hold a webinar on 24 September 2026, led by new Chief Executive Officer Cheri Walker and Financial Controller Suzy Elhlou, to outline the company’s updated strategic direction and discuss its financial results for the 202...
Atomo Diagnostics Files Appendix 4G, Confirms Governance Compliance
Atomo Diagnostics Limited, an ASX-listed medical diagnostics group, operates in the healthcare sector with a focus on rapid testing solutions and structured corporate governance. The company maintains a board charter and formalised executive arrangem...
Atomo Diagnostics Issues Cautious FY26 Results Overview
Atomo Diagnostics has released an overview of its FY26 results, presented as a high‑level information update for investors rather than a detailed financial report. The document emphasises that the material is general in nature, should not be th...
Atomo Diagnostics Lifts Revenue and Narrows Annual Loss
Atomo Diagnostics reported a 41% increase in revenue from ordinary activities to AUD 5.33 million for the year to 30 June 2026, while narrowing its after-tax loss by 29% to AUD 3.51 million. Basic and diluted loss per share improved to 0.425 cents fr...
Atomo Diagnostics Discloses Director John Kelly’s Exit and Ongoing Shareholding
Atomo Diagnostics Ltd. has announced that director John Kelly ceased to be a member of the board on 19 August 2026, formalising the change in governance disclosed to the ASX. The notice confirms his substantial direct and indirect shareholdings and o...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 06, 2026